1871 Folsom Street
About Clovis OncologyClovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado.
April 20, 2009
Founders: Patrick Mahaffy, and Erle Mast
CEO and Co-founder: Patrick Mahaffy
CMO (Medical): Lindsey Rolfe
Please click here for Clovis Oncology job opportunities.
Please click here for clinical trial information.
301 articles with Clovis Oncology
New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline
Initial data from the Phase 1b part of the LIO-1 trial of lucitanib combined with Opdivo® (nivolumab) in advanced metastatic solid tumors identify a recommended Phase 2 dose and show promising signs of antitumor activity
Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that an abstract featuring data from an exploratory analysis of the ARIEL3 clinical study evaluating Rubraca
Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020
Initial presentation of data from the Phase 1b part of the LIO-1 trial of lucitanib in combination with nivolumab in advanced metastatic solid tumors New data analyses for Rubraca ® (rucaparib) from the Phase 2 TRITON2 and Phase 3 ARIEL3 studies in patients with metastatic castration-resistant prostate cancer (mCRPC) and recurrent ovarian cancer, respectively First presentation of preclinical data for FAP-2286, a novel peptide-targeted
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 2:00 p.m. Eastern time.
FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
FDA Approves FoundationOne ® Liquid CDx to Serve as Rubraca ® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2 -Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) FDA-approved plasma-based companion diagnostic provides advantages for patients and practices BOULDER, Colo.--( BUSINESS WIRE )-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) approved the F
Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that data from the Phase 2 TRITON2 study of Rubraca® (rucaparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 mutations were published online in the Journal of Clinical Oncology.
8/10/2020It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2020, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook for the rest of the year
Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers
Initial Phase 1b data from LIO-1 to be presented at the ESMO Virtual Congress 2020 The LIO-1 trial is part of Clovis Oncology’s broad clinical collaboration with Bristol Myers Squibb
Clovis Oncology to Announce Second Quarter 2020 Financial Results and Host Webcast Conference Call on August 6
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2020 financial results on Thursday, August 6, 2020, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis Oncology website at www.clovison
Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020
Clovis Oncology to Highlight Rubraca ® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020
Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca® (rucaparib), a poly (ADP ribose) polymerase inhibitor (PARP), and Bristol-Myers Squibb’s PD-1 inhibitor, OPDIVO
Clovis Oncology Announces New Recommendations for Rubraca® (rucaparib) Tablets in Updated National Comprehensive Cancer Network (NCCN) Guidelines® for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clovis Oncology Announces New Recommendations for Rubraca ® (rucaparib) Tablets in Updated National Comprehensive Cancer Network (NCCN) Guidelines ® for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Rubraca recommended as a treatment option for BRCA-mutant mCRPC in the second line setting and as a subsequent therapy; if the patient is not fit for chemotherapy, rucaparib can be considered prior to taxane
May 21, 2020 20:10 UTC Scientific data describe clinical experience and potential of Rubraca in multiple solid tumor types BOULDER, Colo.--( BUSINESS WIRE )-- Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that six abstracts featuring data from clinical and real-world evidence studies evaluating Rubraca ® (rucaparib) in multiple tumor types have been accepted for presentation or publication at the American Society of Clinical Oncology 2020 Virtual Scientific Program
Clovis Oncology, Inc. announced the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share, before underwriting discounts and commissions.
Clovis Oncology, Inc. announced that it has commenced an underwritten public offering of common stock.
With the new approval, Rubraca becomes the first PARP inhibitor approved in a prostate cancer setting.
Rubraca® Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Receptor-Directed Therapy and a Taxane-Based Chemotherapy
Clovis Oncology, Inc., announced that the U.S. Food and Drug Administration approved Rubraca® tablets for the treatment of adult patients with a deleterious BRCA mutation -associated metastatic castration-resistant prostate cancer who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.
Despite the COVID-19 pandemic, the U.S. Food and Drug Administration has managed to stay fairly on track in terms of evaluating new drug and supplemental new drug applications. Here’s a look at what’s on the schedule for the next two weeks.
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2020, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook for the rest of the year.